Barclays
RCKT icon

Barclays’s Rocket Pharmaceuticals RCKT Stock Holding History

Barclays’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$377K – 5502
2024
Q4 		$377K Hold
30,000
– – ﹤0.01% 3992
2024
Q3 		$554K Buy
+30,000
New +$614K ﹤0.01% 3711
2024
Q2 		– Sell
-47,400
Closed -$1.28M – 5220
2024
Q1 		$1.28M Hold
47,400
– – ﹤0.01% 2921
2023
Q4 		$1.42M Buy
+47,400
New +$1.05M ﹤0.01% 3186
2017
Q1 		– Sell
-5,000
Closed -$122K – 6935
2016
Q4 		$122K Buy
+5,000
New +$143K ﹤0.01% 4605

Other funds holding RCKT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Monaco Asset Management
Monaco Asset Management Monaco $818M AUM 32.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Barclays's RCKT Position: Q3 2026 in Review

Barclays increased its Rocket Pharmaceuticals (RCKT) stake by 183% in Q3 2026, buying an estimated $144K and bringing the position to 64,306 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #4059.

Barclays first reported a position in RCKT in Q4 2015 and has held it in 43 quarters since. The position peaked at $9.6M in Q4 2021. 116 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

  • Barclays held 64,306 shares of Rocket Pharmaceuticals worth $169K as of Q3 2026.
  • Barclays bought 41,590 Rocket Pharmaceuticals shares in Q3 2026, an estimated $144K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4059 holding.
  • Barclays first reported a position in Rocket Pharmaceuticals in Q4 2015 and has held it in 43 quarters since.
  • Barclays's Rocket Pharmaceuticals position peaked at $9.6M in Q4 2021.
  • 116 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.